Southern Ohio Medical Center

Healthcare Leaders Turn to New Screening Technology to Address Workplace Violence

Retrieved on: 
Tuesday, January 23, 2024
Health, Security, Sports, Technology, Hospitals, Managed Care, Surfing, Sailboarding, Southern Ohio Medical Center, Patient, Nursing, Hospital, Workplace violence, RN, Northwell Health, Life, Weapon, School, University, ED, Growth, Environment, Gun, Safety, Express, Violence, WRH

Evolv Technology (NASDAQ: EVLV), the modern security technology company transforming threat and weapons detection to create safer experiences, continues to see growth in the healthcare sector as hospital leaders add advanced weapons detection to their safety plans.

Key Points: 
  • Evolv Technology (NASDAQ: EVLV), the modern security technology company transforming threat and weapons detection to create safer experiences, continues to see growth in the healthcare sector as hospital leaders add advanced weapons detection to their safety plans.
  • With over 70% of workplace violence taking place in a healthcare setting and the majority of emergency physicians saying violence in the emergency department harms patient care, the need to address staff safety has become paramount for many hospital administrators.
  • “We have successfully stopped a significant number of dangerous items from entering our facility with this new system.
  • They wanted to be able to take care of patients and not worry about their safety.

ESAB Corporation Announces Second Quarter 2023 Results

Retrieved on: 
Tuesday, August 1, 2023
Other Transport, Rail, Maritime, Air, Transport, Health, Other Construction & Property, Residential Building & Real Estate, Public Transport, Construction & Property, Finance, Professional Services, Mining, Minerals, General Health, Natural Resources, Other Manufacturing, Steel, General Automotive, Automotive, Engineering, Other Energy, Chemicals, Plastics, Utilities, Automotive Manufacturing, Oil, Gas, Aerospace, Coal, Manufacturing, Alternative Energy, Building Systems, Energy, International, EBX, EBITDA, ESAB, Webcast, Southern Ohio Medical Center, Growth, EPS, PDF, NYSE, Cassette tape, Pharmaceutical industry

ESAB Corporation (“ESAB” or the “Company”) (NYSE: ESAB), a world leader in connected fabrication technology and gas control solutions, today announced record financial results for the second quarter of 2023.

Key Points: 
  • ESAB Corporation (“ESAB” or the “Company”) (NYSE: ESAB), a world leader in connected fabrication technology and gas control solutions, today announced record financial results for the second quarter of 2023.
  • ESAB reported second quarter sales of $720 million, an increase of 9% on a reported basis or 6% higher core organic growth before acquisitions and currency translation impacts, as compared to the prior year quarter.
  • ESAB also reported second quarter net income from continuing operations attributable to ESAB of $67 million or $1.10 diluted earnings per share and core adjusted net income of $74 million or $1.21 diluted earnings per share.
  • The Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2023, filed August 1, 2023, is also available on ESAB’s website under the “Investors” section.

ESAB Corporation Acquires Ohio Medical

Retrieved on: 
Monday, October 17, 2022
Robotics, Medical Supplies, Health, Chemicals, Plastics, Technology, Manufacturing, Steel, Efficiency, Victor, Hand, GCE, LLC, NYSE, Southern Ohio Medical Center, Corporate finance, Private Securities Litigation Reform Act, EPS, Goal, Company, Acquisition, EBX, ESAB, EBITDA, Forward-looking statement, Robotics, Risk management

ESAB Corporation (ESAB or the Company) (NYSE: ESAB), a world leader in fabrication and gas control technology, announced today that it has acquired Ohio Medical, LLC (Ohio Medical), a global leader in oxygen regulators and central gas systems, from a private investor group for a cash purchase price of $127 million.

Key Points: 
  • ESAB Corporation (ESAB or the Company) (NYSE: ESAB), a world leader in fabrication and gas control technology, announced today that it has acquired Ohio Medical, LLC (Ohio Medical), a global leader in oxygen regulators and central gas systems, from a private investor group for a cash purchase price of $127 million.
  • Shyam P. Kambeyanda, President and Chief Executive Officer of ESAB, stated, We are thrilled to welcome the Ohio Medical team to ESAB Corporation.
  • Ohio Medical is headquartered in Gurnee, Illinois and employs approximately 100 associates, providing ESAB with strong brands and distribution in the large and attractive North American market.
  • Combined with ESABs Victor and GCE businesses, the addition of Ohio Medical creates an unmatched global medical and industrial gas control portfolio that enhances the companys worldwide offerings.

Southern Ohio Medical Center Leverages MEDITECH Expanse to Lower Hospital-Acquired C. difficile Rates by 30%

Retrieved on: 
Tuesday, August 30, 2022
Technology, Medical Devices, Medical Supplies, Hospitals, Health Technology, Nanotechnology, Software, Hardware, Managed Care, Health, Mortality, Software, Subclinical infection, Partnership, Disease, KLAS, Documentation, MEDITECH, SOMC, Awareness, Time, RN, Clostridioides difficile (bacteria), EHR, LinkedIn, Antimicrobial stewardship, Southern Ohio Medical Center, MPS, DNP, Goal, Hospital, Â, Software suite, Twitter, Efficiency, Risk, Business, Hospital-acquired infection, Patient, Medicine, Risk management, Facebook

Our performance model is called A Better Way and our team, in partnership with MEDITECH Professional Services, did just that.

Key Points: 
  • Our performance model is called A Better Way and our team, in partnership with MEDITECH Professional Services, did just that.
  • We found a better way to detect C. difficile infections and provide patient treatment earlier on.
  • Southern Ohio Medical Centers commitment to quality improvement really is an investment in their future, she said.
  • See why KLAS rates MEDITECH Expanse the #1 EHR in three categories and the #2 Overall Software Suite.

Rocco Morelli Named Interim CEO of Recombinetics™, Global Leader in Genetically Engineered Animals

Retrieved on: 
Tuesday, January 18, 2022
Health, Genetics, Other Health, General Health, Biotechnology, Veterinary, Board, Genetic engineering, Human, Electrical engineering, Southern Ohio Medical Center, Combat engineer, Loyola University, Growth, Director, Health, CEO, Combat, GE, Mathematics, Leadership, Trustee, Animal, Tissue, Morelli, Vanderbilt University, Marketing, Therapy, Gundersen Health System, Genetics, Miniature pig, Spacelabs Healthcare, Loyola University Chicago, Engineering, Cell, Senior, Xenotransplantation, Management, Finance, Recombinetics, Makana Therapeutics, Recombinetics, MAKANA THERAPEUTICS, RECOMBINETICS

Recombinetics Inc., a global leader in the development, deployment, and commercialization of genetically engineered animals, announced today that Rocco Morelli has been named the companys interim Chief Executive Officer (CEO) effective immediately.

Key Points: 
  • Recombinetics Inc., a global leader in the development, deployment, and commercialization of genetically engineered animals, announced today that Rocco Morelli has been named the companys interim Chief Executive Officer (CEO) effective immediately.
  • Morelli succeeds Mark Platt, who is assuming the role full-time as President and CEO of Makana Therapeutics, a subsidiary of Recombinetics and a leader in the field of xenotransplantation.
  • Recombinetics and Makana have expertise and strong intellectual property positions in clinical organ transplantation, genetic engineering, reproductive technology, and xenotransplantation.
  • Founded in 2008, Recombinetics is a recognized global leader in the development, deployment, and commercialization of genetically engineered animals.

Global Oxygen Flow Meters (Plug-in, Double Flange) Market Size, Share & Trends Analysis Report 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 10, 2021
Medical Devices, Health, Solution, Asia, COVID-19, Disease, Cancer, CAGR, Southern Ohio Medical Center, Industry, Health care, Coronavirus, Adoption, Oxygen, Aquaculture

The "Global Oxygen Flow Meters Market Size, Share & Trends Analysis Report by Type (Plug-in Type, Double Flange Type), by Application (Healthcare, Industrial, Aerospace, Chemical), by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Oxygen Flow Meters Market Size, Share & Trends Analysis Report by Type (Plug-in Type, Double Flange Type), by Application (Healthcare, Industrial, Aerospace, Chemical), by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • This has forced pharmaceutical companies to deliver oxygen supplies, including oxygen flow meters, for such diseases continuously.
  • This is leading to an increased demand for oxygen flow meters across the healthcare sector.
  • North America held a significant market share in 2020 as it is home to several product manufacturers of oxygen flow meters.

NVIGEN to Present Data Demonstrating Highly Sensitive and High NGS Data Efficiency ctDNA Testing with its NVIGEN X® - Cancer Precision Profiling Technology

Retrieved on: 
Tuesday, December 7, 2021
PET, Southern Ohio Medical Center, MRD, Nucleic acid thermodynamics, Multiomics, CT, Technology, NGS, Liquid biopsy, DNA, Patient, Breast cancer, Neoplasm, Recurrence, Nanoparticle, MRI, FDA, Hospital, Cell, Medical imaging

The ultimate goal is to determine the most effective personalized treatment course.

Key Points: 
  • The ultimate goal is to determine the most effective personalized treatment course.
  • "The initial data shown at SABCS elaborate that our NVIGEN X ctDNA and multiomics diagnostic platform has potential to have a profound impact on patient lives by empowering drug developers and clinicians with the tools they need to optimize treatment.
  • The NVIGEN X Cancer Precision Profiling Tests enabled by the state-of-the-art molecularly engineered nanoparticles are developed into accurate, automated and FDA-approved clinical tests deployable at hundreds and thousands of hospitals, with the goal of turning fatal cancers into manageable diseases.
  • NVIGEN holds or has exclusive rights to 10 patents, with an additional 8 patents pending, covering compositions of matter and a wide range of diagnostic and therapeutic applications.